Structure–Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity.

MLA

Kim, Gibae, et al. “Structure–Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity.” Journal of Medicinal Chemistry, vol. 66, no. 17, Sept. 2023, pp. 12249–65. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.3c00806.

APA

Kim, G., Hou, X., Byun, W. S., Kim, G., Jarhad, D. B., Lee, G., Hyun, Y. E., Yu, J., Lee, C. S., Qu, S., Warnick, E., Gao, Z.-G., Kim, J. Y., Ji, S., Shin, H., Choi, J.-R., Jacobson, K. A., Lee, H. W., Lee, S. K., & Jeong, L. S. (2023). Structure–Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity. Journal of Medicinal Chemistry, 66(17), 12249–12265. https://doi.org/10.1021/acs.jmedchem.3c00806

Chicago

Kim, Gibae, Xiyan Hou, Woong Sub Byun, Gyudong Kim, Dnyandev B. Jarhad, Grim Lee, Young Eum Hyun, et al. 2023. “Structure–Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity.” Journal of Medicinal Chemistry 66 (17): 12249–65. doi:10.1021/acs.jmedchem.3c00806.